This article is more than 5 years old. Information may no longer be current.

Mylan Pharmaceuticals launches bromfenac ophthalmic solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PITTSBURGH — Mylan Pharmaceuticals has launched bromfenac ophthalmic solution following a development and supply agreement with Coastal Pharmaceuticals, according to a Mylan press release.

The twice-daily formulation of bromfenac ophthalmic solution 0.09% is the first generic version of Xibrom (Ista Pharmaceuticals), the release said.

For the 12 months ending March 31, 2011, U.S. sales of bromfenac reached approximately $116 million.

Mylan currently has 169 abbreviated new drug applications that are pending approval by the U.S. Food and Drug Administration, 45 of which are potential first-to-file opportunities, according to the release.